Geron Corporation reported third quarter 2025 revenues of $47.2 million, reflecting a 3% decline in net product sales for RYTELO, as the company emphasizes its commitment to increasing utilization and education around its therapy for lower-risk MDS.

• New patient starts for RYTELO increased significantly to 36% from 30% in the previous quarter, despite an overall revenue decline.
• The company expanded its prescribing accounts by 15%, adding approximately 150 new accounts, bringing the total to 1,150.
• Geron is initiating a strategic focus on increasing awareness among healthcare providers and enhancing relationships with key opinion leaders as part of a comprehensive plan to drive sales growth.
• New Chief Commercial Officer, Ahmed ElNawawi, joins to strengthen the execution of Geron’s commercial strategy and address the challenges in the current marketplace.